Search results

Order by most recent / most popular / relevance

Results: 1-9 of 9

Dispelling the Myriad gene patent harmonization myth

Foley & Lardner LLP
-
Australia, Canada, European Union, France, Germany, Japan, USA
-
April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Securing IP in stem cells

Bereskin & Parr LLP
-
Canada, USA
-
April 12 2013

Stem cells are at the centre of research into regenerative medicine. They have the ability to continuously produce newly differentiated cells and

Northern exposure?

Gowling Lafleur Henderson LLP
-
Canada, USA
-
April 4 2013

Davit Akman and John Norman suggest that a recently commenced investigation into alleged "product switching" and statements by the Interim

Life sciences & law current issues 201213

Gowling Lafleur Henderson LLP
-
Canada, European Union, USA
-
June 18 2012

Each stage of the life cycle of a company or a product presents challenges that demand the expertise and resources of a strong legal partner

The U.S. Prometheus decision and claims to methods of optimizing dosing regimens: Mayo Collaborative Services v. Prometheus Laboratories, Inc., U.S., No. 10-1150

Gowling Lafleur Henderson LLP
-
Canada, USA
-
April 11 2012

In a decision last month, the U.S. Supreme Court in a 9-0 ruling has held that the method claims of two patents directed to optimizing the dose of a specific drug for treating an autoimmune disease are not patentable because they merely recite laws of nature

Determining patentable subject matter in the United States and Canada

Bereskin & Parr LLP
-
Canada, USA
-
April 10 2012

As reported in our March 21, 2012, Spring Alert, the United States Supreme Court recently held in Prometheus v. Mayo that certain personalized medicine claims were directed to laws of nature and were thus unpatentable despite containing both an administering step and a determining step

Biosimilar battlegrounds - what is new in biosimilars and where?

Bereskin & Parr LLP
-
Canada, European Union, USA
-
February 17 2012

Biosimilars are second entry biologic drugs

Confirmation of the patentability of DNAgene sequences in the United States

Borden Ladner Gervais LLP
-
Canada, USA
-
December 21 2011

Canadian courts showed promising support for DNAgene patents by ruling in favour of Monsanto in its often-cited patent infringement case

Amendments relating to prior US and Canadian proceedings allowed in statement of claim

Borden Ladner Gervais LLP
-
Canada, USA
-
August 31 2011

This is an appeal from an Order of a Prothonotary, allowing the Plaintiffs’ motion to amend its Second Amended Statement of Claim

Search results

Dispelling the Myriad gene patent harmonization myth

Securing IP in stem cells

Northern exposure?

Life sciences & law current issues 201213

The U.S. Prometheus decision and claims to methods of optimizing dosing regimens: Mayo Collaborative Services v. Prometheus Laboratories, Inc., U.S., No. 10-1150

Determining patentable subject matter in the United States and Canada

Biosimilar battlegrounds - what is new in biosimilars and where?

Confirmation of the patentability of DNAgene sequences in the United States

Amendments relating to prior US and Canadian proceedings allowed in statement of claim

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea